Brief: SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study For SAB-142, A Novel Immunotherapeutic For Type 1 Diabetes At FORCIS 2023

SAB Biotherapeutics

21/06/2023 13:37

June 21 (Reuters) - SAB Biotherapeutics Inc  SABS.O :
    * SAB BIOTHERAPEUTICS PRESENTS POSITIVE IND-ENABLING GLP
TOXICOLOGY STUDY FOR SAB-142, A NOVEL IMMUNOTHERAPEUTIC FOR TYPE
1 DIABETES AT FOCIS 2023
    * SAB BIOTHERAPEUTICS INC - STUDY SHOWS SAB'S FULLY-HUMAN
MULTI-TARGET IMMUNE MODULATING THERAPEUTIC FOR TREATMENT OF TYPE
1 DIABETES IS WELL TOLERATED
    * SAB BIOTHERAPEUTICS INC - PLANS TO SUBMIT IND APPLICATION
FOR
SAB-142 TO U.S. FDA AND INITIATE A PHASE 1 TRIAL IN NEXT FEW
MONTHS

Source text for Eikon:  ID:nGNX75CMNh 
Further company coverage:  SABS.O 

 (Reuters.Briefs@thomsonreuters.com)